B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42
B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42
Bof A證券將Rhythm Pharmicals的評級下調至中性，將目標股價下調至42美元
B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral and lowers the price target from $49 to $42.
B of A Securities分析師塔澤恩·艾哈邁德將Rythm Pharmicals（納斯達克股票代碼：RYTM）的評級從買入下調至中性，並將目標股價從49美元下調至42美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。